Here’s Why Inovio Pharmaceuticals Is Soaring (Again) Today
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were up by 21.4% as of 3:12 p.m. EDT on Friday. The market is likely responding to a Thursday evening CNBC interview of the company's CEO, Dr. Joseph Kim.
Inovio recently kicked off a phase 1 clinical trial to test the safety of its investigational COVID-19 vaccine, INO-4800. The trial -- which will involve up to 40 healthy adult volunteers -- will also test the vaccine's ability to trigger an immune response in the body. During the CNBC interview with Jim Cramer, Kim said the company plans to finish enrolling volunteers for the trial before the end of the month.
Kim also said that getting the company's investigational COVID-19 vaccine on the market within 12 to 18 months was not out of the question. In his own words: "It's possible, especially if you have a platform that's shown to be safe and if you have tested similar approaches before against other pathogens, like we have."
Source Fool.com
